By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.

Based on multiplexed ion beam imaging, the system, which the company plans to launch next year, will compete most directly with Fluidigm's Hyperion platform.

The deal will join CGI's portfolio of cancer tests and lab services with NovellusDx's technologies for cancer treatment response prediction.

The appropriations package would boost the NIH's fiscal 2019 budget to $39.1 billion, and earmarks money for programs such as the All of Us initiative.

The survey, conducted by SeraCare Life Sciences and GenomeWeb, asked more than 150 individuals working on clinical NGS about their quality control practices.

The firm has been placing point-of-care systems primarily in the private sector, but may have increased access once it completes WHO prequalification review.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

➢ Human induced pluripotent stem cell (iPSC) technology has provided unique ways to understand and
potentially treat human diseases using cells from individual patients.
➢ iPS cells are amenable to genomic modifications using site-specific gene editing technologies such as
CRISPR/Cas9, by which we can correct/ introduce precise disease causing mutations in patient or healthy
iPSCs, respectively.
➢ Genome edited iPSCs and their isogenic control (or parental line) offer highly-controlled experimental models
for reliable comparison of results.

The goal of this experiment was to utilize the Echo 525 Liquid Handler in assembling five, five-piece assemblies by substituting modular DNA pieces at the nanoliter scale. The Labcyte Echo Liquid Handler enables lower-cost methods and workflows to produce high-quality synthetic DNA constructs.

Introduction to In Vivo Probe Validation:

Before beginning a large animal study, it is critical to confirm that your labeled targeting agent is specific to the intended target within the biological complexity of the whole animal. Understanding the biodistribution and clearance of a labeled targeting agent is critical for meaningful image analysis and interpretation. This guide will provide an overview of how to validate a targeting agent in vivo.